

Trust Headquarters
 Russell's Hall Hospital
 Dudley
 West Midlands
 DY1 2HQ

Ref: FOI-000333

Date: 29/9/23

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Name of medicine	Number patients treated
1.1 Abemaciclib (Verzenios)	27
1.2 Alpelisib (Piqray)	Cannot specify
1.3 Fulvestrant (fulvestrant or Faslodex)	24
1.4 Palbociclib (Ibrance)	52
1.5 Ribociclib (Kisqali)	Cannot specify

Q2. How many patients received abemaciclib (Verzenios) for **early breast cancer** in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Number patients treated
4

Q3. How many patients received abemaciclib (Verzenios) as **adjuvant treatment for early breast cancer** in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Number patients treated
2

Q4. How many patients received abemaciclib (Verzenio) with the following treatment intent in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Treatment intent	Number patients treated
4.1 Curative	6
4.2 Palliative	14
4.3 Not known / stated	1

Q5. How many patients were treated with the following medicines in combination in the 3 months between the start of June 2023 and end of August 2023?

Please provide data for the latest 3-month period, if Jun to Aug is not available yet

Name of combination or monotherapy	Number patients treated
5.1 Abemaciclib (Verzenio) + Fulvestrant (fulvestrant or Faslodex)	7
5.2 Abemaciclib (Verzenio) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	20
5.3 Abemaciclib (Verzenio) + tamoxifen	0
5.4 Abemaciclib monotherapy	0
5.5 Alpelisib (Piqray) + Fulvestrant (fulvestrant or Faslodex)	Cannot specify
5.6 Palbociclib (Ibrance) + Fulvestrant (fulvestrant or Faslodex)	9
5.7 Palbociclib (Ibrance) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	0
5.8 Ribociclib (Kisqali) + Fulvestrant (fulvestrant or Faslodex)	Cannot specify
5.9 Ribociclib (Kisqali) + an aromatase inhibitor (anastrozole, letrozole or exemestane)	Cannot specify

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113

FOI/REF FOI-

www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust